Sector: University & Research Institutions

Latest content

UPC holds first ever preliminary injunction hearing

NanoString Technologies is facing an injunction at the UPC, which has scheduled several further PI hearings in Munich and Vienna

06 September 2023

‘We want to de-risk the CRISPR-Cas9 patent minefield’, says Sigma-Aldrich IP licensing boss

IAM speaks exclusively to Christopher Arnot about the crowded CRISPR IP landscape

25 August 2023

UPC schedules its first substantive hearings

Having granted its first injunction ex parte, the Unified Patent Court will soon host formal hearings regarding 10x Genomics’ applications for injunctive relief

22 August 2023

We are seeking CRISPR IP partnerships, says SNIPR Biome’s chief patent counsel

IAM speaks exclusively to Jasper Clube about the CRISPR microbiome IP landscape

18 August 2023

Who is who: key players in the global RIS patent landscape

RIS has received attention from a diverse number of players working towards creating SEP portfolios. As the technology progresses and becomes more sophisticated and with the standardisation process underway, an acceleration of patent filings in the coming years is very likely.

02 August 2023

CRISPR patent interference overturned by Federal Circuit

SNIPR Biome has five patents revived but more disputes are on the horizon

18 July 2023

UPC looks set for first antitrust spat in unusual life sciences dispute

The plot continues to thicken in 10x Genomics’ multi-faceted spat with NanoString

13 July 2023

First unitary patent assertion occurs on UPC day one, as 10x Genomics follows up on German success

After winning first ever biotech AASI, 10x Genomics files first ever UP lawsuit

06 June 2023

A roadmap for industry-academia collaboration to advance IP policy

Ethical and transparent partnerships can help resolve pressing issues all while furthering a company’s goals and interests

08 March 2023

Boston Scientific ordered to hand University of Texas $42 million in David-versus-Goliath dispute

But patentee worried further action could ‘exhaust’ it as MedTech company moves to appeal

07 February 2023

Unlock unlimited access to all IAM content